Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

No explicit numerical revenue or EPS guidance was provided for 2026, but the company reaffirmed its focus on expanding the installed base and driving utilization, aiming for "approximately 120" ...

Profound Medical (NASDAQ:PROF) reported fourth-quarter 2025 revenue of $6.0 million, including $2.3 million in recurring ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, ...

CAMC Urology recently performed his 100th robotic high intensity focused ultrasound (HIFU) procedure, an advanced treatment for patients with prostate cancer.

Stage and screen actor Robert Lindsay, 76, is the 100,000th signature to the petition calling for prostate cancer screening ...

The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.

Abstract: Objective: Surgical workflow understanding, especially surgical phase and step recognition, plays a crucial role for improving context-aware computer-assisted system in modern operating room ...

The probability of surgical success with telesurgery for radical prostatectomy and partial nephrectomy for small renal masses was non-inferior to local robotic surgery in a small randomized trial. The ...